Pharmaceutical firm Cipla on Friday announced that its wholly-owned UK subsidiary — Cipla EU — has signed definitive agreements for equity investment of EUR15 million in Ethris GmbH for the development of messenger RNA (mRNA)-based therapies.
Ad Blocker Enabled!
Ad Blocker Enabled!
Our website is made possible by displaying online advertisements to our visitors. Please support us by disabling your Ad Blocker.
